Good summary, BearDown. In my view, after many years preclinical and clinical research, there's no chance BP is not going to pick up apabetalone. It's just a question of the details and the price. And there's been no pressure of time to reach a deal, because who wants to start a P3 in the middle of a pandemic? They know what P=0.11 means. Yes, it means BoM "failed" but it also means there's an 89/100 probability the drug actually was actually effective. That represents pretty good odds.